Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics

At a glance

This paper describes the characteristics of ALS patients with Medicare

Affiliates

Rituparna Bhattacharya1, Raymond A Harvey1, Keli Abraham1, Jon Rosen1, Paul Mehta2

  1. Humana Inc.
  2. Agency for Toxic Substances and Disease Registry, Division of Toxicology and Human Health Services

Journal

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Summary

This study estimates ALS prevalence and survival in participants with Medicare. The 5-year period prevalence was 20.5 per 100,000. The 2011-point prevalence for ALS was 11.8 per 100,000. Analyses using Medicare data resulted in higher ALS prevalence estimates than previously reported.

Link to paper

Find the paper here!

Print
Content Source:
Agency for Toxic Substances and Disease Registry